Martin Hülsmann

Digitoxin in Patients with Heart Failure and Reduced Ejection Fraction

DIGitoxin to Improve Outcomes in Patients with Advanced Chronic Heart Failure (DIGIT-HF): Baseline Characteristics Compared to Recent Randomized Controlled Heart Failure Trials

The DIGIT-HF Trial: Key Amendments of Study Design

Simple and safe digitoxin dosing in heart failure based on data from the DIGIT-HF trial

Renin Trajectories and Outcome in Stable Heart Failure with Reduced Ejection Fraction (HFrEF) on Contemporary Therapy: A Monocentric Study from an Austrian Tertiary Hospital Outpatient Clinic.

Cardiac remodelling – Part 1: From cells and tissues to circulating biomarkers. A review from the Study Group on Biomarkers of the Heart Failure Association of the European Society of Cardiology

Cardiac remodelling – Part 2: Clinical, imaging and laboratory findings. A review from the Study Group on Biomarkers of the Heart Failure Association of the European Society of Cardiology

Principal Morphomic and Functional Components of Secondary Mitral Regurgitation

Integration of imaging and circulating biomarkers in heart failure: a consensus document by the Biomarkers and Imaging Study Groups of the Heart Failure Association of the European Society of Cardiology

Increased concentrations of bioactive adrenomedullin subsequently to angiotensin-receptor/neprilysin-inhibitor treatment in chronic systolic heart failure.

Secondary mitral regurgitation-Insights from microRNA assessment.

Natural History of Functional Tricuspid Regurgitation

GDF-15 in solid vs non-solid treatment-naïve malignancies.

Phenotyping progression of secondary mitral regurgitation in chronic systolic heart failure.

Advanced Heart Failure: A Position Statement of the Heart Failure Association of the European Society of Cardiology

Circulating bile acids predict outcome in critically ill patients